IFI35 limits antitumor immunity in triple-negative breast cancer via CCL2 secretion. Xu B, Sun H, Liu S, Liao L, et al. Oncogene 2024 Jan 12. doi: 10.1038/s41388-023-02934.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Xu B, Sun H, Liu S, Liao L, et al. IFI35 limits antitumor immunity in triple-negative breast cancer via CCL2 secretion. Oncogene 2024 Jan 12. doi: 10.1038/s41388-023-02934.
PMID: 38216673